Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Salubris secures funding to advance complex biologics for various diseases
The company intends to utilise the funds to continue its ongoing Phase Ib clinical trial and begin two additional Phase Ib studies this year. It also plans to
The company intends to utilise the funds to continue its ongoing Phase Ib clinical trial and begin two additional Phase Ib studies this year. It also plans to
A drug-free nasal spray, Bentrio is designed for personal protection against airborne viruses and allergens. It forms a protective gel layer on the nasal mucosa upon application into
As per the terms of the updated and restated deal, Helsinn will obtain an exclusive license for infigratinib commercialisation in the US. The company will also develop, produce,
The funding round included new investors Schroders Capital, 3B Future Health Fund, Caribou Property, and British Patient Capital. Existing investors Epidarex Capital and ALSA Ventures have also participated
Co-led by Canaan Partners and Red Tree Venture Capital, the financing round included significant investment from Johnson & Johnson Innovation – JJDC. SV Health Investors and Novo Holdings
Daprodustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that is indicated to treat anaemia of CKD in adult patients not on dialysis and on dialysis.
The regulatory agency issued a complete response letter (CRL) to the company’s New Drug Application (NDA) for lenacapavir mentioning Chemistry Manufacturing and Controls (CMC) issues related to its
Jointly developed and commercialised by Pharmacyclics, Imbruvica (ibrutinib) is a once-daily oral medication that blocks the Bruton’s tyrosine kinase (BTK) protein. The sNDA seeks approval for the drug
Keytruda is Merck’s an anti-programmed death receptor-1 (PD-1) therapy that increases the ability of the immune system in body for detecting and fighting tumour cells. It is a
The investigational, phosphodiesterase 4B (PDE4B) inhibitor, BI 1015550 has the potential to address pulmonary fibrosis as well as inflammation linked to progressive fibrosing interstitial lung diseases (ILDs). Pulmonary